MDM2 promotes the proliferation and inhibits the apoptosis of pituitary adenoma cells by directly interacting with p53

Abstract

Introduction: Pituitary adenomas constitute one of the most common intracranial tumours. The mouse double minute 2 homologue (MDM2) is considered as an important oncogene in many tumours, but it has been little studied in pituitary adenomas and the mechanism is not well understood. The purpose of this study was to investigate the function of MDM2 and its primary mechanism of action in pituitary adenoma cells. Material and methods: The expression of MDM2 in pituitary adenoma cell lines and normal cells was determined by real-time polymerase chain reaction (RT-PCR). The proliferation and apoptosis of pituitary adenoma cells after inhibition of MDM2 expression were detected by MTS and flow cytometry, respectively. The protein expressions of MDM2 and p53 were detected by western blot. Co-IP was used to detect the direct binding between MDM2 and p53. Results: The results of RT-PCR showed that MDM2 was significantly up-regulated in pituitary adenoma cell lines. Inhibition of MDM2 suppressed the proliferation and promoted apoptosis of pituitary adenoma cells. However, inhibiting the expression of MDM2 can promote the protein expression of p53. The results of co-IP showed that MDM2 interacted with p53 by direct combination. Then, we inhibited the expressions of p53 and MDM2 simultaneously in the pituitary adenoma cells by co-transfecting siRNAs, and the results showed that, compared with the group that inhibited MDM2 alone, cell proliferation of the co-transfected group increased and apoptosis of the cotransfected group decreased, which was similar to the NC group. Conclusions: Taken together, these results suggest that MDM2 promoted the proliferation and inhibited the apoptosis of pituitary adenoma cells by directly interacting with p53 in pituitary adenoma cells. Therefore, MDM2-p53 may serve as a novel marker and therapeutic target for pituitary adenomas.

Identification of Molecular Biomarkers Associated With Stroke Progression Using WGCNA and SVM-RFE

“…Akt mediates the phosphorylation of MDM2 in Ser166 and Ser186 and increases its interaction with p300, so MDM2 mediates the ubiquitination and degradation of p53 (Liu et al,2020). Phosphorylation of MDM2 also blocks its binding to p19ARF and increases the p53 degradation (Wang et al,2020). It can be seen that many genes are involved in stroke through their interactions.…”

Cushing hastalığının etyopatogenezinde genomik değişiklikler ve moleküler mekanizmalar

“…MDM2'nin hipofiz tümörlerinde doğrudan p53 ile etkileşerek hücre çoğalmasını arttırdığı, apoptozu baskıladığı gösterilmiştir. Bu nedenle, hipofiz tümörlerinin tedavisinde MDM2-p53 birlikteliği hedeflenebilir (38) . Ayrıca, MDM2/ p53 kompleksinin mir-219a-2-3p tarafından baskılanabildiği düşünüldüğünde, miRNA'ların da hipofiz tümörlerinin tanısında bir belirteç olarak kullanılabileceği düşünülebilir Ayrıca, hipofiz adenomlarının patolojik incelemesinde p53'ün genellikle negatif olduğu, çok nadir görülen hipofiz karsinomlarının tümünde pozitif olduğu gözlenmiştir.…”

Potential Molecular Target Prediction and Docking Verification of Hua‐Feng‐Dan in Stroke Based on Network Pharmacology

“…Akt mediates the phosphorylation of MDM2 at Ser166 and Ser186, increasing its interaction with p300, so that MDM2 mediates the ubiquitination and degradation of p53 [30]. Phosphorylation of MDM2 also blocks its binding to p19ARF and increases the degradation of p53 [31].…”